(HealthDay News) — Fish oil supplementation is associated with atherothrombotic risk reduction in suspected coronary artery disease (CAD), according to a study published in The American Journal of Cardiology.
Christopher J. Franzese, from the Sinai Hospital in Baltimore, and colleagues compared indices of atherothrombotic risk in 600 patients with suspected CAD who were on fish oil supplementation or not on fish oil supplementation.
Results indicated that fish oil supplementation correlated with significantly increased eicosapentaenoic acid plus ocosahexaenoic acid content and with significantly lower triglycerides, total VLDL cholesterol, intermediate-density lipoprotein cholesterol and AtherOx levels; these correlations were not seen in patients on lipid-lowering therapy.
VLDL cholesterol, intermediate-density lipoprotein cholesterol, remnant lipoproteins, triglycerides, LDL cholesterol, AtherOx levels, collagen-induced platelet aggregation, thrombin-induced platelet-fibrin clot strength and shear elasticity were lower for patients not on lipid-lowering therapy taking fish oil supplementation.
There was no difference in ADP-induced aggregation between fish oil supplementation groups for clopidogrel-treated patients.
Regardless of lipid-lowering therapy, patients on fish oil supplementation had lower urinary 11-dehydrothromboxane B2 levels.
“Future prospective studies to compare [fish oil supplementation] with lipid-lowering therapy and to assess the independent effects of [fish oil supplementation] on thrombogenicity are needed,” the researchers wrote.
Several authors disclosed financial ties to the pharmaceutical industry; one author disclosed holding patents in the area of personalized antiplatelet therapy and interventional cardiology.